Navigation Links
Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
Date:5/23/2013

SEATTLE, May 23, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia. OMS824 has shown promising results in animal models directly relevant to Huntington's disease and, as previously announced, OMS824 was well tolerated and exhibited favorable pharmacokinetic properties in a Phase 1 clinical program. Omeros plans to advance OMS824 into Phase 2 clinical trials for Huntington's disease next quarter and for schizophrenia later this year, the OMS824 IND for use in patients with schizophrenia having already been cleared by the FDA.

Omeros also announced today that it has requested Orphan Drug Designation from the FDA for OMS824 in the treatment of Huntington's disease. Orphan-designated drugs are eligible for incentives such as a faster approval process and additional market exclusivity. This designation is granted to drugs that are expected to provide significant therapeutic advantage over existing treatments and that target conditions affecting 200,000 or fewer U.S. patients annually. Huntington's disease is estimated to affect approximately 31,000 U.S. patients annually, and the only FDA‑approved treatment for the disease is tetrabenazine, which is indicated for Huntington's-related movement disorders. Omeros recently announced that it has requested Fast Track designation for OMS824 in the treatment for Huntington's disease. Fast Track designation is reserved for drugs being developed to treat life-threatening conditions with the potential to address unmet medica
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
2. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
3. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
4. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
5. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
6. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
7. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
8. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
9. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
10. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
11. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "Investment Analysis of the ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the US medical device sector identifies the key ... venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a global leader ... today announced it will participate in the 33 rd ... in San Francisco . ... speak at 11:00 AM Pacific Time.  A live audio webcast ... Investor Relations link on the Cyberonics home page at ...
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... March 17 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... ended December 31, 2007, and provided an update,on the ... "During 2007 and the first quarter of 2008, we ... an important transitional year for,Alexza, as we initiate the ...
... Eye via,Ophthalmic Artery, WASHINGTON, March 17 ... -- a,deadly, inherited cancer of one or both ... having their eyes surgically removed (enucleated),according to the ... Society of,Interventional Radiology,s 33rd Annual Scientific Meeting. Advanced,retinoblastoma ...
Cached Medicine Technology:Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 2Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 3Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 4Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 5Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 6Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 7Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 8Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 9Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 10Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 11Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 12Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 13Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 14New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 2New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 3New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 4
(Date:12/24/2014)... 2014 Today, UWDress.com, the famous women’s dress ... gowns, and launched a site-wide wedding gown promotion. ... gowns in a more unexpected way, the collection should be ... in the global market, and they are available with custom ... offered at discounted prices, up to 75% off; most of ...
(Date:12/24/2014)... Oregon (PRWEB) December 24, 2014 ... Rehab sat down with Derek Fenwick, PT, MBA, ... changes that will stem from the passing of the ... (IMPACT Act). In this taping of the Infinicast, ... title XVIII of the Social Security Act to standardize ...
(Date:12/24/2014)... The holidays can be a challenge for people who suffer ... drinks. "This is the season in which many people ... David Dodick, chair of the American Migraine Foundation, said in ... think through food and beverage choices, to help reduce the ... of neurology at the Mayo Clinic in Scottsdale, Ariz. , ...
(Date:12/24/2014)... Adults who experienced childhood abuse or neglect have ... study published online Dec. 24 in the journal ... long-lasting effects, like associated medical and psychological conditions ... director of behavioral medicine at Montefiore Headache Center ... news release. "When managing patients with migraine, ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- A lab technician with ... have been exposed to the Ebola virus in an ... up to a dozen other lab workers are being ... afternoon. The possible exposure occurred Monday when CDC ... of the potentially lethal virus to another CDC lab ...
Breaking Medicine News(10 mins):Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2
... Guaranteed Healthcare, AFL-CIO Secretary Treasurer Richard Trumka to Keynote ... ... Patients, First Responders to Join Emotional September 11th Rally With ... Californians, OAKLAND, Calif., Sept. 6 The California Nurses,Association/National ...
... to Support EIF,s Women,s ... Cancer Research Fund, ... edition version of its all-new, eagerly-awaited 2008,C350 Sport Sedan to raise ... initiative developed in partnership with the Entertainment,Industry Foundation,s (EIF) Women,s Cancer ...
... will participate in a nationwide study to pinpoint the ... infection. , The objective of this trial is ... people who have MRSA, said David Karras, professor and ... Medicine and Hospital, who will lead the research efforts ...
... Tim McGraw and Friends, ... Presented by Anheuser-Busch Companies, NAPA, Calif., Sept. 6 ... on Friday, Nov. 2 at Grant,s Farm,the ancestral home of ... "Denim & Diamonds: An Evening with Tim McGraw and,Friends". Proceeds ...
... Predictive medicine company,PreMD Inc. (TSX: PMD; Amex: PME) ... U.S. Food and Drug Administration (FDA) regarding its,510(k) ... POC skin,cholesterol test. PreMD submitted the 510(k) application ... to obtain broader clearance in the assessment of,cardiovascular ...
... may open a window of vulnerability for developing binge ... according to a study from the University of North ... , In a long-term study of 100,000 pregnant Norwegian ... incidences of binge eating disorder that began during pregnancy. ...
Cached Medicine News:Health News:Hundreds of RNs from Across U.S. and World to Join California Nurses Association/NNOC National Convention 2Health News:Mercedes-Benz Special Edition C350 Sport Sedan to Raise $1 Million for Saks Fifth Avenue's KEY TO THE CURE 2Health News:Mercedes-Benz Special Edition C350 Sport Sedan to Raise $1 Million for Saks Fifth Avenue's KEY TO THE CURE 3Health News:Mercedes-Benz Special Edition C350 Sport Sedan to Raise $1 Million for Saks Fifth Avenue's KEY TO THE CURE 4Health News:Temple Emergency Medicine receives $1.8M to find best MRSA treatment 2Health News:Temple Emergency Medicine receives $1.8M to find best MRSA treatment 3Health News:The Tug McGraw Foundation Announces 2007 Fundraising Gala 2Health News:The Tug McGraw Foundation Announces 2007 Fundraising Gala 3Health News:The Tug McGraw Foundation Announces 2007 Fundraising Gala 4Health News:PreMD Provides Update on 510(k) Application for PREVU(x) POC 2Health News:Pregnancy may increase the risk of developing binge eating disorder 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: